Basilea Pharmaceutica AG
BPMUF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$944.88M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $944.88 Million |
|---|---|
| Enterprise Value | $853.92 Million |
| Earnings per Share | $3.29 |
| Beta | 0.41 |
| Outstanding Shares | 12,370,195 |
Return
| Return on Equity | 72.13% |
|---|---|
| Return on Assets | 39.29% |
| Return on Invested Capital | 48.13% |
Valuation & Multiples
| P/E Ratio | 16.08 |
|---|---|
| PEG | 6.34 |
| Price to Sales | 2.24 |
| Price to Book Ratio | 5.87 |
| Enterprise Value to Revenue | 1.98 |
| Enterprise Value to EBIT | 6.92 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$4.14
Consensus analyst estimateRevenue Estimate
$133.24 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 16, 2027
EPS Estimate
$3.49
Consensus analyst estimateRevenue Estimate
$182.16 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Basilea Pharmaceutica AG
189 employees
CEO: David Veitch
Basilea Pharmaceutica AG is a revenue-generating biopharmaceutical company dedicated to developing innovative products to meet critical medical needs in both cancer treatment (oncology) and the fight against infections (anti-infectives)....